Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today
that George S. Barrett, Chief Executive Officer, Teva North America,
Corporate Executive VP, Global Pharmaceutical Markets has resigned
from the Company and that William S. Marth, currently President and
Chief Executive Officer of Teva USA, will replace Mr. Barrett and
assume the additional role of Chief Executive Officer of Teva North
America effective immediately. Mr. Barrett, who is leaving to become
Vice Chairman of Cardinal Health and CEO of its Healthcare Supply
Chain Services Sector, will remain with Teva through the end of
January 2008 to assist in the transition.

Mr. Marth, age 53, who has 30 years experience in the
pharmaceutical industry and close to a decade with Teva, will be
responsible for North America, including the U.S. Mr. Marth has run
the U.S. generics business where he has handled much of the day-to-day
commercial activities since his appointment as EVP in 2002 and has
been President and Chief Executive Officer of Teva USA since 2005. He
has overseen a number of significant product launches, most notably
the December launch of generic Protonix, and two of the largest
launches in the history of U.S. generics, Simvastatin and Pravastatin
in 2006. Mr. Marth, will continue to be based in Teva’s North American
headquarters in North Wales, PA and will report directly to Teva
President and CEO, Shlomo Yanai.

“We greatly appreciate George’s leadership and the significant
contributions he has made to Teva over the years and wish him
continued success in the future,” said Teva’s President and CEO Shlomo
Yanai. “Teva has never been more solidly positioned in the North
American market than it is today and given Bill’s enormous success in
leading our U.S. generics business, he is the obvious choice to assume
this role. With Bill’s deep industry experience, training and
institutional knowledge of Teva, I am confident that he will continue
to lead us to growth in this critical region.”

Mr. Barrett added, “Leaving Teva was a very difficult decision for
me, as I have enjoyed working with so many colleagues, both here and
around the world, building this unique global pharmaceutical company.
I will leave knowing that Teva’s global leadership team is strong and
that Bill, with whom I have worked so closely over the years and his
entire team in North America, will continue their enormous
contributions to Teva’s growth.”

“This is a particularly exciting time for Teva and I look forward
to building on our success in North America and having an even greater
role with the investment community. George has been not only a
colleague but also a friend and someone whom I have learned a great
deal from over the many years that we’ve worked side-by-side and I
wish him all the best,” said Mr. Marth.

Mr. Marth assumed the position of president and CEO of Teva USA in
2005. Prior to that, he served as Executive Vice President and as Vice
President of Sales and Marketing of Teva USA. Before joining the
Company, Mr. Marth served in various leadership positions with the
Apothecon Division of Bristol-Myers Squibb. Mr. Marth serves on
various boards and committees, including the Teva Executive Committee
and as Vice Chairman of the Generic Pharmaceutical Association (GPhA).
Mr. Marth has a B.Sc. in pharmacy from the University of Illinois and
an M.B.A. from the Keller Graduate School of Management in Chicago,
Illinois.

About Teva

Teva Pharmaceutical Industries Ltd., headquartered in Israel, is
among the top 20 pharmaceutical companies in the world and is the
leading generic pharmaceutical company. The company develops,
manufactures and markets generic and innovative human pharmaceuticals
and active pharmaceutical ingredients. Over 80 percent of Teva’s sales
are in North America and Europe.

Safe Harbor Statement under the U. S. Private Securities
Litigation Reform Act of 1995:

This release contains forward-looking statements, which express
the current beliefs and expectations of management. Such statements
are based on management’s current beliefs and expectations and involve
a number of known and unknown risks and uncertainties that could cause
Teva’s future results, performance or achievements to differ
significantly from the results, performance or achievements expressed
or implied by such forward-looking statements. Important factors that
could cause or contribute to such differences include risks relating
to: Teva’s ability to accurately predict future market conditions
including pricing and margins with regard to sales of the generic
version of Protonix(R), potential liability for sales of generic
products prior to a final resolution of outstanding patent litigation,
including that relating to the generic versions of Allegra(R),
Neurontin(R), Lotrel(R) Famvir(R) and Protonix(R), Tevas ability to
successfully develop and commercialize additional pharmaceutical
products, the introduction of competing generic equivalents, the
extent to which Teva may obtain U.S. market exclusivity for certain of
its new generic products and regulatory changes that may prevent Teva
from utilizing exclusivity periods, competition from brand-name
companies that are under increased pressure to counter generic
products, or competitors that seek to delay the introduction of
generic products, the impact of consolidation of our distributors and
customers, the effects of competition on our innovative products,
especially Copaxone(R) sales, the impact of pharmaceutical industry
regulation and pending legislation that could affect the
pharmaceutical industry, the difficulty of predicting U.S. Food and
Drug Administration, European Medicines Agency and other regulatory
authority approvals, the regulatory environment and changes in the
health policies and structures of various countries, our ability to
achieve expected results though our innovative R&D efforts, Teva’s
ability to successfully identify, consummate and integrate
acquisitions, potential exposure to product liability claims to the
extent not covered by insurance, dependence on the effectiveness of
our patents and other protections for innovative products, significant
operations worldwide that may be adversely affected by terrorism,
political or economical instability or major hostilities, supply
interruptions or delays that could result from the complex
manufacturing of our products and our global supply chain,
environmental risks, fluctuations in currency, exchange and interest
rates, and other factors that are discussed in Teva’s Annual Report on
Form 20-F and its other filings with the U.S. Securities and Exchange
Commission. Forward-looking statements speak only as of the date on
which they are made and the Company undertakes no obligation to update
or revise any forward-looking statement, whether as a result of new
information, future events or otherwise.

source